局部晚期不可切除胰腺癌的明确放疗：历史回顾，现状和未来方向

IF 3.2 3区医学 Q3 ONCOLOGY

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI:10.1016/j.semradonc.2025.07.002

Anjalika R. Kumar , Nina N. Sanford

{"title":"局部晚期不可切除胰腺癌的明确放疗：历史回顾，现状和未来方向","authors":"Anjalika R. Kumar , Nina N. Sanford","doi":"10.1016/j.semradonc.2025.07.002","DOIUrl":null,"url":null,"abstract":"<div><div>Based on available Level 1 evidence, standard dose conventional chemoradiation does not improve survival in patients with locally advanced pancreas cancer (LAPC), thus chemotherapy remains the only widely accepted therapy. Yet prognosis remains poor, and despite the negative trial outcomes, most would contend that the addition of radiotherapy does confer benefit in a subset of patients with LAPC. This work reviews the published data, then discusses several key considerations for designing radiotherapy trials in LAPC including choosing clinically meaningful patient-centered endpoints, optimizing patient selection and standardizing target volume delineation. Lastly, we review several promising single arm studies on dose-escalated radiotherapy in LAPC which have paved the way for upcoming Phase III randomized trials assessing this strategy.</div></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"35 4","pages":"Pages 510-513"},"PeriodicalIF":3.2000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Definitive Radiotherapy for Locally Advanced Unresectable Pancreatic Cancer: Historical Review, Current State and Future Directions\",\"authors\":\"Anjalika R. Kumar , Nina N. Sanford\",\"doi\":\"10.1016/j.semradonc.2025.07.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Based on available Level 1 evidence, standard dose conventional chemoradiation does not improve survival in patients with locally advanced pancreas cancer (LAPC), thus chemotherapy remains the only widely accepted therapy. Yet prognosis remains poor, and despite the negative trial outcomes, most would contend that the addition of radiotherapy does confer benefit in a subset of patients with LAPC. This work reviews the published data, then discusses several key considerations for designing radiotherapy trials in LAPC including choosing clinically meaningful patient-centered endpoints, optimizing patient selection and standardizing target volume delineation. Lastly, we review several promising single arm studies on dose-escalated radiotherapy in LAPC which have paved the way for upcoming Phase III randomized trials assessing this strategy.</div></div>\",\"PeriodicalId\":49542,\"journal\":{\"name\":\"Seminars in Radiation Oncology\",\"volume\":\"35 4\",\"pages\":\"Pages 510-513\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in Radiation Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1053429625000578\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053429625000578","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

根据现有的一级证据，标准剂量的常规放化疗不能提高局部晚期胰腺癌（LAPC）患者的生存率，因此化疗仍然是唯一被广泛接受的治疗方法。然而，预后仍然很差，尽管试验结果消极，但大多数人认为放疗的增加确实会给一部分LAPC患者带来好处。本工作回顾了已发表的数据，然后讨论了在LAPC中设计放疗试验的几个关键考虑因素，包括选择临床有意义的以患者为中心的终点，优化患者选择和标准化靶体积描绘。最后，我们回顾了几项在LAPC中剂量递增放疗的有希望的单组研究，这些研究为即将到来的评估该策略的III期随机试验铺平了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Definitive Radiotherapy for Locally Advanced Unresectable Pancreatic Cancer: Historical Review, Current State and Future Directions

Based on available Level 1 evidence, standard dose conventional chemoradiation does not improve survival in patients with locally advanced pancreas cancer (LAPC), thus chemotherapy remains the only widely accepted therapy. Yet prognosis remains poor, and despite the negative trial outcomes, most would contend that the addition of radiotherapy does confer benefit in a subset of patients with LAPC. This work reviews the published data, then discusses several key considerations for designing radiotherapy trials in LAPC including choosing clinically meaningful patient-centered endpoints, optimizing patient selection and standardizing target volume delineation. Lastly, we review several promising single arm studies on dose-escalated radiotherapy in LAPC which have paved the way for upcoming Phase III randomized trials assessing this strategy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in Radiation Oncology 医学-核医学

CiteScore

5.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.